PTC Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG PTC Therapeutics est Matt Klein, nommé en Mar2023, a un mandat de 1.67 ans. La rémunération annuelle totale est $ 8.94M, composée du salaire de 8.4% et des bonus 91.6%, y compris les actions et options de la société. détient directement 0.068% des actions de la société, d'une valeur de € 2.28M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.7 ans et 9.4 ans.

Informations clés

Matt Klein

Directeur général

US$8.9m

Rémunération totale

Pourcentage du salaire du PDG	8.4%
Durée du mandat du directeur général	1.7yrs
Propriété du PDG	0.07%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	9.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Matt Klein a-t-elle évolué par rapport aux bénéfices de PTC Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$453m
Jun 30 2024	n/a	n/a	-US$480m
Mar 31 2024	n/a	n/a	-US$579m
Dec 31 2023	US$9m	US$747k	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

Rémunération vs marché: La rémunération totale de Matt ($USD 8.94M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.93M ).

Rémunération et revenus: La rémunération de Matt a augmenté alors que l'entreprise n'est pas rentable.

PDG

Matt Klein (52 yo)

1.7yrs

Titularisation

US$8,937,025

Compensation

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% € 2.3m
Stuart Peltz	Co-Founder	26.8yrs	US$5.66m	pas de données
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% € 537.2k
Pierre Gravier	Chief Financial Officer	1.3yrs	US$3.01m	0.015% € 519.1k
Mark Boulding	Executive VP & Chief Legal Officer	12.7yrs	US$2.19m	0.063% € 2.1m
Eric Pauwels	Chief Business Officer	9.6yrs	US$2.41m	0.026% € 858.3k
Lee Golden	Executive VP & Chief Medical Officer	4.5yrs	US$2.39m	0.019% € 646.9k
Christine Utter	Senior VP	5.4yrs	US$1.70m	0.022% € 741.9k
Neil Almstead	Chief Technical Operations Officer	5.9yrs	US$2.67m	0.054% € 1.8m
Linda Carter	Senior VP & Chief Information Officer	less than a year	pas de données	pas de données
Alex Kane	Investor Relations Officer	no data	pas de données	pas de données
Jane Baj	Vice President of Corporate Communications	no data	pas de données	pas de données

5.7yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de BH3 est chevronnée et expérimentée (5.7 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% € 2.3m
Stuart Peltz	Co-Founder	1.7yrs	US$5.66m	pas de données
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% € 537.2k
Michael Schmertzler	Independent Chairman of the Board	23.3yrs	US$816.96k	1.95% € 65.3m
David Southwell	Independent Director	18.9yrs	US$438.98k	0.014% € 456.7k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Emma Reeve	Independent Director	5.9yrs	US$441.98k	0.0093% € 313.4k
Joseph Puglisi	Member of Scientific Advisory Board	21yrs	pas de données	pas de données
Glenn Steele	Independent Director	9.4yrs	US$426.98k	0.014% € 456.7k
Marvin Wickens	Member of Scientific Advisory Board	no data	pas de données	pas de données
Robert Schneider	Member of Scientific Advisory Board	no data	pas de données	pas de données
Stephanie Okey	Independent Director	5.9yrs	US$421.98k	0.0076% € 255.4k

9.4yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BH3 sont considérés comme expérimentés (ancienneté moyenne 9.4 ans).

PTC Therapeutics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

CEO & Director recently sold €250k worth of stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold €57k worth of stock

Co-Founder recently sold €110k worth of stock

Co-Founder recently sold €80k worth of stock

Recent updates

PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients

PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$1.39 loss per share (vs US$1.76 loss in 3Q 2023)

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.29 loss per share (vs US$2.66 loss in 2Q 2023)

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$1.20 loss per share (vs US$1.89 loss in 1Q 2023)

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Share price stability

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Full year 2023 earnings released: US$8.37 loss per share (vs US$7.79 loss in FY 2022)

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

CEO & Director recently sold €250k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

New major risk - Financial position

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

New minor risk - Profitability

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$2.66 loss per share (vs US$2.13 loss in 2Q 2022)

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

First quarter 2023 earnings released: US$1.89 loss per share (vs US$1.78 loss in 1Q 2022)

CEO, COO & Director recently sold €57k worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings released: US$7.79 loss per share (vs US$7.44 loss in FY 2021)

Co-Founder recently sold €110k worth of stock

Co-Founder recently sold €80k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.89 loss in 3Q 2021)

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

Insider recently sold €116k worth of stock

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates

Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.68 loss in 2Q 2021)

PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022

PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

First quarter 2022 earnings released: US$1.78 loss per share (vs US$1.83 loss in 1Q 2021)

PTC Therapeutics, Inc. Provides Earnings Guidance for 2022

Insufficient new directors